Palvella Unveils Third QTORIN Program: Topical Docetaxel for EMPD
PVLA has more than doubled off its 52-week low of $72.225.
Summary
Palvella announced QTORIN docetaxel, a third QTORIN platform candidate targeting Extramammary Paget's disease, with IND-enabling work underway and an FDA meeting planned for 1H 2027.
Key Events · Product Development and Regulatory · PVLA
-
Third QTORIN Program Announced
QTORIN docetaxel targets Extramammary Paget's disease, a rare genital and perianal skin cancer with no FDA-approved therapy and an estimated more than 10,000 U.S. patients.
-
Early-Stage Development Timeline
IND-enabling activities have been initiated; Palvella plans an FDA meeting in 1H 2027 and a Phase 2 study afterward under the 505(b)(2) pathway.
-
Evidence Base Is External
The rationale rests on published real-world I.V. docetaxel data — 51.6% ORR in 93 patients, with 52.7% Grade 3+ neutropenia and 24.7% discontinuing for adverse events — not on Palvella's own clinical trial results.
-
No Capital Impact
The 8-K is an Item 7.01/8.01 disclosure with a presentation and press release; no financing, share issuance, or change to the $236.7 million cash position reported for September 30.
Analysis · PVLA · Life Sciences
Palvella has added a third pipeline asset: QTORIN docetaxel for Extramammary Paget's disease, a rare genital and perianal skin cancer with no FDA-approved therapy and an estimated more than 10,000 U.S. patients. The program is early — IND-enabling work has started, an FDA meeting is planned for 1H 2027, and a Phase 2 study would follow — so it adds pipeline breadth and a new multi-billion-dollar TAM claim rather than near-term revenue. Supporting evidence comes from real-world I.V. docetaxel data (51.6% ORR in 93 patients), not from Palvella's own clinical results. Meanwhile, the lead asset, QTORIN rapamycin, is already under FDA Priority Review following the October 28 NDA acceptance. Investors get a broader platform story ahead of that review, but no new cash, no dilution, and no change to the near-term regulatory calendar.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PVLA was trading at $147.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $72.23 to $179.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.